Japan’s AKP Takes Over Artisan To Progress ART-123
This article was originally published in PharmAsia News
Executive Summary
Japan's Asahi Kasei Pharma announced Nov. 22 that its acquisition of Massachusetts-based Artisan Pharma, a company it spun out in 2006.
You may also be interested in...
The Long Goodbye: Lilly Finally Kicks Troubled Sepsis Drug Xigris To The Curb
Eli Lilly & Co. announced Oct. 25 that it is ending its ten-year relationship with Xigris, withdrawing the sepsis drug from all markets and ceasing further clinical trials.
Artisan, Singapore's A-Bio Join Forces On Recombinant Sepsis Candidate
Artisan Pharma and Singapore-based A-Bio Pharma have established a relationship under which the Asian firm will provide process development, scale-up and manufacturing support for Artisan's investigational recombinant protein ART-123, the firms announced Sept. 17
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.